All Clinical Trials in Canada

A listing of 3905 clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

Canada

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

Feasibility and Acceptability of Group Medical Visits for Anxiety and Depression

NCT06651801

Recruiting

The goal of this clinical trial is to evaluate the feasibility and acceptability of the intervention, Group Medical Visits (GMVs), for patients with depression and anxiety. It also aims to get some initial information on the effectiveness of GMVs on reducing depression and anxiety scores, which will help inform power calculations for a future larger randomized controlled trial (RCT). The main question it aims to answer is: * Are GMVs feasible and acceptable to patients with depression and anxie... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/09/2025

Locations: PsycHealth Centre, Winnipeg, Manitoba

Conditions: Mental Health Care, Anxiety and Depression, Pilot Study

Learn More ›

Women's Heart Attack Research Program: Stress Ancillary Study

NCT02914483

Recruiting

The Women's HARP study is a multi-center study focusing on women with clinical presentation of myocardial infarction (MI). Women will complete stress questionnaires following presentation to the medical center with elevated cardiac enzymes and abnormal electrocardiograms (ECGs). 2 months following MI, participants will be screened for the Stress Ancillary Study and enrolled if an elevated level of perceived stress is reported. After completing baseline assessments, participants will be randomize... Read More

Gender:

FEMALE

Ages:

Between 21 years and 99 years

Trial Updated:

05/08/2025

Locations: Cedars-Sinai Medical Center, Los Angeles, California +13 locations

Conditions: Myocardial Infarction

Learn More ›

Pre-Op THA Modelling

NCT05221554

Recruiting

Replacing diseased hip joints with prosthetic implants in a procedure called total hip arthroplasty (THA) is associated with high rates of patient satisfaction, pain relief, and functional improvement when the implant is appropriately placed. Incorrect implant size or placement may lead to a breadth of negative outcomes, which could result in the need for implant revision. It is difficult to assess the precise orientation of patient hips on the operating table, with one study revealing that only... Read More

Gender:

ALL

Ages:

40 years and above

Trial Updated:

05/08/2025

Locations: London Health Sciences Centre, London, Ontario

Conditions: Total Hip Arthroplasty, Computer-Assisted Surgery

Learn More ›

Safety, Tolerability, and Preliminary Efficacy of Psilocybin Oral Solution in Adults With Generalized Anxiety Disorder

NCT06969170

Recruiting

This Phase 2a clinical trial is designed to evaluate the safety, tolerability, and preliminary efficacy of a 3 mg dose of psilocybin oral solution for the treatment of Generalized Anxiety Disorder (GAD). The study consists of three sequential phases: Screening Phase (up to 4 weeks), Open-label Run-in Phase (4 weeks), Double-blind Treatment Phase (4 weeks) Screening Phase During the Screening Visit, participants will provide informed consent and undergo a comprehensive medical evaluation, inclu... Read More

Gender:

ALL

Ages:

Between 18 years and 60 years

Trial Updated:

05/08/2025

Locations: Kingston General Health Research Institute, Kingston, Ontario

Conditions: Generalized Anxiety Disorder (GAD)

Learn More ›

Anteroposterior Versus Anterolateral Electrode Position for Electrical Cardioversion of Atrial Fibrillation

NCT05511389

Recruiting

Atrial fibrillation is the most common heart rhythm disorder (arrhythmia) worldwide. Nearly 40 million people are affected by atrial fibrillation worldwide, and this number is expected to increase by over 50% by 2050. Atrial fibrillation can cause strokes, heart attacks, heart failure, poor quality of life and even death. Almost half a million deaths worldwide are expected to be related to atrial fibrillation by 2050, and many billions of dollars are spent on atrial fibrillation related healthcare in North America every year. We believe health outcomes for patients with atrial fibrillation, and healthcare costs associated with treating atrial fibrillation could be improved by optimizing existing treatments for atrial fibrillation and maximizing the likelihood of restoring normal heart rhythm. This allows them to benefit from lower stroke risk, better heart function, fewer symptoms and increased quality of life. Restoring normal sinus rhythm earlier prevents atrial fibrillation from causing permanent structural damage to the heart that in turn, makes atrial fibrillation intractable. Furthermore, patients in whom initial attempts to control atrial fibrillation are unsuccessful frequently require more medications or invasive catheter ablation procedures which are costly and carry substantial risk. Electrical cardioversion is the main way physicians restore normal heart rhythm. In this procedure, the heart is "shocked" back into normal rhythm using two electrodes on the chest. Done correctly, this procedure is safe and effective. Many things are known about electrical cardioversion, for example, the best type and amount of electricity to use. What we don't know is the best position of the electrodes on the chest and whether applying direct, physical pressure to the electrodes makes cardioversion more successful. Our prior research suggests that improving positioning and applying pressure may improve cardioversion, but this finding needs to be verified with a rigorous, dedicated trial. This study will demonstrate whether front-to-back, or front-to-side placement of the electrodes is more effective for electrical cardioversion of atrial fibrillation. We will also demonstrate whether manually applying pressure to the electrodes makes cardioversion more effective. Should our trial demonstrate a benefit for these techniques, we expect them to be universally applied around the world. Because hundreds of thousands of cardioversions are done each year, even small increases in cardioversion success means thousands fewer patients progress to needing more medications or invasive procedures to manage their atrial fibrillation. We will study consenting adults presenting for non-urgent cardioversion of their atrial fibrillation. After explaining the study to participants and gaining their consent, we will randomly assign them to front-to-side or front-to-back electrode placement. Patients who remain in atrial fibrillation after the first shock will randomly receive either manual pressure or not. We will compare the success of cardioversion for front-side versus front-back electrode placement, and for manual pressure versus none. We will evaluate success by using electrocardiograms to assess for restoration of the heart rhythm back to normal. We hypothesize that anterolateral electrode positioning is superior to anteroposterior electrode positioning. We also hypothesize that manual pressure is effective relative to none, when applied in patients who have had one unsuccessful shock already. Read Less

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/08/2025

Locations: Hamilton Health Sciences, Hamilton, Ontario +1 locations

Conditions: Atrial Fibrillation, Atrial Flutter

Learn More ›

A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of ANX007 in Participants With Geographic Atrophy (GA)

NCT06510816

Recruiting

The primary purpose of the study is to determine if IVT injections of ANX007 every month reduce vision loss in participants with GA secondary to age-related macular degeneration (AMD).

Gender:

ALL

Ages:

50 years and above

Trial Updated:

05/08/2025

Locations: Retina Macula Institute of Arizona, Scottsdale, Arizona +116 locations

Retina Macula Institute of Arizona, Scottsdale, Arizona

Retina-Vitreous Associates Medical Group, Beverly Hills, California

RCOC Clinical Research Institute Inc, Fullerton, California

Global Research Management, Glendale, California

Retina Consultants Medical Group, Modesto, California

Northern California Retina Vitreous Associates Medical Group, Inc., Mountain View, California

Retina Consultants of San Diego, Poway, California

Retinal Consultants Medical Group, Sacramento, California

California Retina Consultants- Santa Barbara, Santa Barbara, California

Macula Retina Vitreous Research Institute, Torrance, California

Bay Area Retina Associates, Walnut Creek, California

Retina Consultants of Southern Colorado PC, Colorado Springs, Colorado

RSC Research, LLC, Denver, Colorado

Retina Consultants, P.C., Manchester, Connecticut

Rand Eye Institute, Deerfield Beach, Florida

National Ophthalmic Research Institute, Fort Myers, Florida

Florida Retina Institute- Jacksonville, Jacksonville, Florida

Florida Retina Institute, Orlando, Florida

Fort Lauderdale Eye Institute, Plantation, Florida

Retina Vitreous Associates of Florida, Saint Petersburg, Florida

Retina Group of Florida, Sarasota, Florida

East Florida Eye Institute, Stuart, Florida

Southern Vitreoretinal Associates, Tallahassee, Florida

Georgia Retina PC, Marietta, Georgia

Retina Consultants of Hawaii, 'Aiea, Hawaii

Retina Associates - Elmhurst Location, Elmhurst, Illinois

Illinois Retina Associates, S.C., Oak Park, Illinois

Springfield Clinic LLP, Springfield, Illinois

Wolfe Eye Clinic, West Des Moines, Iowa

Retina Associates of Kentucky, Lexington, Kentucky

Maine Eye Center, Portland, Maine

Retina Group of Washington, Chevy Chase, Maryland

Cumberland Valley Retina Consultants, Hagerstown, Maryland

Mid Atlantic Retina Specialists, Hagerstown, Maryland

Ophthalmic Consultants of Boston, Boston, Massachusetts

Retina Research Institute at New England Retina Consultants, Springfield, Massachusetts

Retina Consultants of Minnesota, Saint Louis Park, Minnesota

Sierra Eye Associates, Reno, Nevada

Envision Ocular, LLC, Bloomfield, New Jersey

Mid Atlantic Retina, Cherry Hill, New Jersey

Vision Research Center Eye Associates of New Mexico, Albuquerque, New Mexico

Long Island Vitreoretinal Consultants, Hauppauge, New York

Vitreous Retina Macula Consultants of NY (VRMNY), New York, New York

Asheville Eye Associates - Retina Division, Asheville, North Carolina

North Carolina Retina Associates, Wake Forest, North Carolina

Piedmont Retina Specialists - Winston Salem Office, Winston-Salem, North Carolina

University Hospitals Cleveland Medical Center, Cleveland, Ohio

Cleveland Clinic Foundation, Cleveland, Ohio

Retina Vitreous Center, Edmond, Oklahoma

Tulsa Retina Consultants, Tulsa, Oklahoma

Verum Research, LLC, Eugene, Oregon

Eyehealth Northwest Portland, Portland, Oregon

Cascade Medical Research Institute, Springfield, Oregon

Erie Retina Research, LLC, Erie, Pennsylvania

Eye Care Specialists, Kingston, Pennsylvania

Palmetto Retina Center, Aiken, South Carolina

ReƟna Consultants of Charleston, Beaufort, South Carolina

Charleston Neuroscience Center, Charleston, South Carolina

Retina Research Institute of Texas, Abilene, Texas

Southwest Retina Specialists, Amarillo, Texas

Texas Retina Associates- Arlington, Arlington, Texas

Austin Research Center for Retina, Austin, Texas

Austin Retina Associates, Austin, Texas

Austin Clinical Research, LLC, Austin, Texas

Retina Consultants of Texas, Bellaire, Texas

Retina Foundation of the Southwest, Dallas, Texas

Texas Retina Associates - Plano, Dallas, Texas

Texas Retina Associates, Fort Worth, Texas

Retina Consultants of Texas, Katy, Texas

Tennessee Retina PC, Nashville, Texas

Retina Consultants of Texas San Antonio, San Antonio, Texas

Retina Consultants of Texas, Schertz, Texas

Retina Consultants of Texas, The Woodlands, Texas

Strategic Clinical Research Group, LLC, Willow Park, Texas

Rocky Mountain Retina Consultants, Salt Lake City, Utah

Salt Lake Retina, West Jordan, Utah

Piedmont Eye Center, Lynchburg, Virginia

Eye Clinic of Wisconsin, Wausau, Wisconsin

Eye Clinic Albury Wodonga, Albury, New South Wales

Strathfield Retina Clinic, Melbourne, New South Wales

Marsden Eye Specialists, Parramatta, New South Wales

Sydney Eye Hospital, Sydney, New South Wales

Sydney Retina Clinic and Day Surgery, Sydney, New South Wales

Kepler Universitätsklinikum, Linz, Not set

Calgary Retina Consultants, Calgary, Alberta

Alberta Retina Consultants, Edmonton, Alberta

Ivey Eye Institute, London, Ontario

Retina Centre of Ottawa, Ottawa, Ontario

Toronto Western Hospital -UHN, Toronto, Ontario

Fakultní nemocnice Královské Vinohrady, Praha 10, Not set

Axon Clinical, s.r.o. Ocni Klinika, Praha 5, Not set

Service d'Ophtalmologie Centre Hospitalier Intercommunal de Créteil, Creteil, Not set

CHU Dijon Bourgogne - Hôpital François Mitterrand, Dijon Cedex, Not set

Dietrich Bonhoeffer Klinikum Klinik für Augenheilkunde, Neubrandenburg, Mecklenburg Vorpommern

Augenzentrum am St. Franziskus-Hospital, Muenster, North Rhine-Westphalia

Universitätsklinikum Tübingen, Department für Augenheilkunde, Tübingen, Not set

Semmelweis Egyetem, Budapest, Not set

Budapest Retina Associates, Budapest, Not set

Ganglion Medical Center, Pecs, Not set

IRCCS Ospedale San Raffaele, Milano, Not set

Elisabeth Hospital (ETZ) - location TweeSteden ziekenhuis, Tilburg, Not set

Southern Eye Specialists, Christchurch, Canterbury

Capital Eye Specialists, Te Aro, Wellington

Oftalmika Sp.Zo.O., Bydgoszcz, Not set

Centrum Diagnostyki I Mikrochirurgii Oka Lens Sp. Z O.O., Olsztyn, Not set

Caminomed Sp. Z O.O., Tarnowskie Góry, Not set

Warszawski Szpital Okulistyczny, Warsaw, Not set

Oftalvist IMED Burjassot, Valencia, Burjasso

Institut Català de Retina, Barcelona, Not set

Hospital Universitari Vall d'Hebron, Barcelona, Not set

Hospital de la Arruzafa - Metavisión Arruzafa, Cordoba, Not set

Hospital Universitario Puerta de Hierro - Majadahonda, Majadahonda, Not set

Hospital Universitario Virgen Macarena, Sevilla, Not set

Hospital Clínico Universitario Lozano Blesa, Zaragoza, Not set

Hospital Universitario Miguel Servet, Zaragoza, Not set

Moorfields Eye Hospital NHS foundation Trust, London, Not set

The Retina Clinic, London, Not set

Conditions: Geographic Atrophy

Learn More ›

A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)

NCT05668988

Recruiting

This is a phase 3, open-label, randomized, multi-center study assessing the efficacy and safety of DZD9008 versus platinum-based doublet chemotherapy in participants with locally advanced or metastatic NSCLC with EGFR Exon20ins mutation, who are newly diagnosed or have not received prior systemic therapy in advanced stage. Primary objective of this study is to assess the efficacy of DZD9008 versus platinum-based doublet chemotherapy using by BICR-assessed PFS per RECIST 1.1 as primary endpoint.... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/08/2025

Locations: OPN Healthcare, Inc., Glendale, California +159 locations

OPN Healthcare, Inc., Glendale, California

Kaiser Permanente Medical Center, Vallejo, California

University of Colorado Hospital - Anschutz Cancer Pavilion, Aurora, Colorado

D&H Cancer Research Center, Margate, Florida

Brcr Global, Plantation, Florida

H. Lee Moffitt Cancer Center, Tampa, Florida

NYU Laura & Issac Perlmutter Cancer Center, New York, New York

Columbia University Medical Center, New York, New York

Gabrail Cancer Center Research, Canton, Ohio

The Ohio State University, Columbus, Ohio

Providence Portland Medical Center, Portland, Oregon

USOR - Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas

MD Anderson cancer center, Houston, Texas

USOR - Texas Oncology--Weslaco, Weslaco, Texas

University of Virginia Comprehensive Cancer Center, Charlottesville, Virginia

Centro de Educación Médica e Investigaciones Clínicas, CEMIC, Buenos Aires, Not set

Centro Diabaid, Buenos Aires, Not set

Centro Medico Austral, Buenos Aires, Not set

Consultorios Medicos Dr. Doreski - Fundacion Respirar, Buenos Aires, Not set

Fundacion Cenit Para El Estudio De Neurociencias, Buenos Aires, Not set

Hospital Italiano de Buenos Aires (HIBA), Buenos Aires, Not set

Instituto Alexander Fleming, Buenos Aires, Not set

Instituto Argentino de Diagnositco y Tratamiento S.A, Buenos Aires, Not set

Fundación Estudios Clínicos, Rosario, Not set

Fundación Ars Médica, San Salvador, Not set

Centro de Investigación Clínicas. Clinica Viedma S.A, Viedma, Not set

Concord Cancer Centre Medical Oncology Clinical Trials Unit Concord Repatriation General Hospital, Concord, Not set

Peter MacCallum Cancer Centre, Melbourne, Not set

Sir Charles Gairdner Hospital, Heart Research Insititute, Nedlands, Not set

Prince of Wales Hospital, Randwick, Not set

Ordensklinikum Linz GmbH Elisabethinen, Linz, Not set

Uniklinikum Salzburg, Salzburg, Not set

Antwerpen University Hospital (UZA), Edegem, Antwerp

University Hospital Gent- Drug Research Unit Ghent (D.R.U.G.), Ghent, Flanders

Grand Hopital de Charleroi (GHdC) - Hopital Notre Dame, Charleroi, Hainaut

Fundacao PIO XII - Hospital do Cancer de Barretos, Barretos, Not set

Centro de Pesquisas Clinicas em, Cachoeiro De Itapemirim, Not set

Liga Norte Riograndense Contra o Câncer, Natal, Not set

Hospital São Lucas da PUCRS, Porto Alegre, Not set

Santa Casa de Misericordia- Porto Alegre - Hospital Santa Rita, Porto Alegre, Not set

Instituto D'Or de Pesquisa e Ensino - Recife, Recife, Not set

Instituto America(COI), Rio De Janeiro, Not set

Instituto D'Or de Pesquisa e Ensino, Rio De Janeiro, Not set

Instituto Nacional de Cancer Jose Alencar Gomes da Silva, Rio De Janeiro, Not set

Instituto do Cancer do Estado de Sao Paulo - ICES, São Paulo, Not set

Regional Cancer Program London Health Sciences Centre, London, Not set

The Ottawa Hospital Cancer Center, Ottawa, Not set

Princess Margaret Cancer Center, Toronto, Not set

Beijing Cancer Hospital, Beijing, Not set

Beijing Chest Hospital, Capital Medical University, Beijing, Not set

Cancer Hospital of the Chinese Academy of Medical Sciences, Beijing, Not set

Peking Union Medical College Hospital, Beijing, Not set

Peking University Third Hospital, Beijing, Not set

Hunan Cancer Hospital, Changsha, Not set

West China Hospital of Sichuan University, Chengdu, Not set

Army Medical Center of PLA, Chongqing, Not set

Chongqing Cancer Hospital, Chongqing, Not set

Fujian Cancer Hospital, Fuzhou, Not set

Fujian Medical University Union Hospital, Fuzhou, Not set

The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Not set

The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Not set

The First Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Not set

Zhejiang Cancer Hospital, Hangzhou, Not set

Harbin Medical University Cancer Hospital, Harbin, Not set

Anhui Provincial Hospital, Hefei, Not set

The First Affiliated Hospital of Anhui Medical University, Hefei, Not set

The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Not set

Jilin Cancer Hospital, Jilin, Not set

Central Hospital Affiliated to Shandong First Medical University, Jinan, Not set

Shandong Cancer Hospital & Institution, Jinan, Not set

Yunnan Cancer Hospital, Kunming, Not set

The Second Affiliated Hospital of Nanchang University, Nanchang, Not set

Jiangsu Cancer Hospital, Nanjing, Not set

Jiangsu Provincial Hospital, Nanjing, Not set

Guangxi Medical University Cancer Hospital, Nanning, Not set

Shanghai Chest Hospital, Shanghai, Not set

Shanghai Pulmonary Hospital, Shanghai, Not set

ZhongShan Hospital Fudan University, Shanghai, Not set

The First Hospital of China Medical University, Shenyang, Not set

Cancer Hospital Chinese Academy of Medical Sciences, ShenZhen center, Shenzhen, Not set

The Fourth Hospital of Hebei Medical University, Shijiazhuang, Not set

Shanxi Provincial Cancer Hospital, Taiyuan, Not set

Taizhou Hospital of Zhejiang Province, Taizhou, Not set

Tianjin Medical University Cancer Institute & Hospital, Tianjin, Not set

Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology, Wuhan, Not set

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Not set

The First Affiliated Hospital of Xi 'an Jiaotong University, Xi'an, Not set

Yantai Yuhuangding Hospital, Yantai, Not set

Henan Cancer Hospital, Zhengzhou, Not set

The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Not set

Fakultni Nemocnice Olomouc (FNOL) - Onkologicka Klinika, Olomouc, Not set

Vitkovicka Nemocnice a.s. - Plicni oddeleni, Ostrava, Not set

Centre Hospitalier Universitaire d'Angers, Angers, Not set

Hôpital Louis Pradel, Bron, Not set

Centre Hospitalier Intercommunal de Creteil (CHIC), Créteil, Not set

Centre Hospitalier Universitaire de Lille (CHU Lille) - Hopital Albert Calmette - Clinique des Maladies Respiratoires, Hellemmes-Lille, Not set

Centre Hospitalier Universitaire Grenoble Alpes (CHU Grenoble Alpes) - Hopital Albert Michallon, La Tronche, Not set

APHM-Hôpital NORD, Marseille, Not set

Centre de Cancérologie Montpellier, Montpellier, Not set

APHP Hôpital Tenon, Paris, Not set

Cochin Hospital, Paris, Not set

Hopital Saint Joseph, Paris, Not set

Hôpital Bichat - Claude Bernard, Paris, Not set

CHU Poitiers, Poitiers, Not set

Centre Hospitalier Universitaire de Nantes (CHU de Nantes), Saint Herblain, Not set

Institut de Cancerologie de L'Ouest, Saint Herblain, Not set

Hopital d'Instruction Des Armees Begin, Saint-Mande, Not set

Hopital Foch, Suresnes, Not set

Evangelische Lungenklinik Berlin - Klinik fuer Pneumologie, Berlin, Not set

Asklepios Klinik Gauting GmbH - Klinik fuer Thorakale Onkologie, Gauting, Not set

Niels-Stensen-Kliniken - Franziskus-Hospital Harderberg, Georgsmarienhütte, Not set

Universitaetsklinikum Heidelberg (UKHD) - Thoraxklinik-Heidelberg gGmbH, Heidelberg, Not set

Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz - III. Medizinische Klinik und Poliklinik, Mainz, Not set

Pius-Hospital Oldenburg - Klinik fuer Haematologie und Onkologie, Oldenburg, Not set

Centro di Riferimento Oncologico (CRO Aviano), Aviano, Not set

Azienda Ospedaliero Universitaria di Bologna - Policlinico S. Orsola-Malpighi, Bologna, Not set

Azienda Ospedaliero - Universitaria "Policlinico-Vittorio Emanuele" Catania, Catania, Not set

Università degli Studi di Firenze - Azienda Ospedaliero-Universitaria Careggi (AOUC) - SC di Oncologia MedicaI, Florence, Not set

Azienda USL Toscana Sud Est -Ospedale Misericordia - Grosseto, Grosseto, Not set

Servizio Sanitario Regionale Emilia-Romagna - Istituto Scientifico Romagnolo per lo Studio e La Cura dei Tumori Srl (IRST), Meldola, Not set

Azienda Ospedaliero-Universitaria di Modena (AOU Modena) - Policlinico di Modena, Modena, Not set

Azienda Ospedaliera San Gerardo - Monza, Monza, Not set

La Maddalena Casa di Cura di Alta Specialita - Palermo, Palermo, Not set

Azienda Ospedaliero-Universitaria di Parma, Parma, Not set

Azienda Unità Sanitaria Locale Romagna, Ravenna, Not set

Azienda Ospedaliera di Reggio Emilia - Arcispedale S. Maria Nuova (ASMN), Reggio Emilia, Not set

IRCCS Istituti Fisioterapici Ospitalieri- Istituto Nazionale tumori Regina Elena, Roma, Not set

Azienda Ospedaliera Universitaria Senese - Istituto Toscano Tumori (ITT) - Center for Immuno-Oncology (CIO), Siena, Not set

Universiteit Maastricht (UM) - Maastricht University Medical Centre (Maastricht UMC+), Maastricht, Not set

Uniwersyteckie Centrum Kliniczne, Klinika Onkologii i Radioterapii, Gdańsk, Not set

MED-POLONIA Sp. z o.o., Poznań, Not set

Wojewódzki Szpital im. św. Ojca Pio, Przemyśl, Not set

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie Panstwowy, Warsaw, Not set

Complejo Hospitalario Universitario A Coruña, A Coruña, Not set

Hospital de la Santa Creu i Sant Pau, Barcelona, Not set

Hospital Universitari Vall d'Hebron, Barcelona, Not set

Institut Catala d'Oncologia Badalona (ICO Badalona) - Hospital Germans Trias i Pujol, Barcelona, Not set

Instituto Oncológico Dr Rosell Hospital Quiron Dexeus, Barcelona, Not set

UOMI Cancer Center - Clinica Tres Torres, Barcelona, Not set

Institut Catala d'Oncologia de Girona -Hospital Universitari Dr Josep Trueta, Girona, Not set

Hospital Universitario de Jerez, Jerez De La Frontera, Not set

Clínica Universidad de Navarra - Madrid, Madrid, Not set

Hospital HM Sanchinarro, Madrid, Not set

Hospital Universitario 12 de Octubre, Madrid, Not set

Hospital Universitario Fundación Jiménez Diaz, Madrid, Not set

Hospital Universitario La Paz, Madrid, Not set

Hospital Regional Universitario de Málaga, Málaga, Not set

Hospital Universitario Virgen de Valme, Sevilla, Not set

Hospital Universitario Virgen del Rocio, Sevilla, Not set

Hospital Universitario Virgen Macarena, Sevilla, Not set

Hospital Clinico Universitario de Valencia, Valencia, Not set

Hospital Universitari i Politècnic La Fe, Valencia, Not set

Ankara Bilkent City Hospital Universiteler Mahallesi, Ankara, Not set

Dr. Abdurrahman Yurtaslan Ankara Oncology Training, Ankara, Not set

Gazi Universitesi Tip Fakultesi (Gazi University Faculty of Medicine) - Gazi Hastanesi (Gazi Hospital), Ankara, Not set

Liv Hospital Ankara - Medical Oncology Clinic, Ankara, Not set

Trakya Universitesi Saglik Arastirma ve Uygulama Merkezi Hastane, Edirne, Not set

Bezmialem University Hospital, Istanbul, Not set

Prof. Dr. Süleyman Yalçın Şehir Hastanesi - Tibbi Onkoloji Klinigi, Kadıköy, Not set

Necmettin Erbakan University, Konya, Not set

Conditions: Non-small Cell Lung Cancer

Learn More ›

Evaluation of Stool Based Markers for the Early Detection of Colorectal Cancers and Adenomas

NCT00843375

Recruiting

Colon cancer is the second most common cancer in men and women. It is a disease that can be prevented if it is found early. Colonoscopy is still the best screening tool for colon cancer and the polyps that turn into colon cancer. However, due to a variety of factors, including affordability, time, and age, not all patients are able to be screened. Researchers are working on other options for early detection that are as accurate as colonoscopy. The purpose of this study if to determine if stool... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/07/2025

Locations: Cedars-Sinai Medical Center, Los Angeles, California +12 locations

Conditions: Colonic Neoplasms

Learn More ›

Transdiagnostic Internet Cognitive-behavior Therapy for Mixed Anxiety and Depressive Symptoms in Postnatal Women

NCT06778096

Recruiting

This research project aims to examine the acceptability and efficacy of a French-Canadian adaptation of a postnatal anxiety and depression program. The main question it aims to answer is: \[1\] When the adapted postnatal Internet-delivered cognitive behavioral therapy (iCBT) is added to treatment as usual (TAU) in community-based care for women with anxiety and depressive symptoms, is the iCBT+TAU condition more effective to reduce symptoms than TAU alone? Participants will: postnatal iCBT gr... Read More

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

05/07/2025

Locations: Centre intégré de santé et services sociaux de la Montérégie-Ouest, Châteauguay, Quebec +3 locations

Conditions: Anxiety, Postnatal Depression

Learn More ›

Conversion From Unresectable To Resectable Metastatic Colorectal Cancer.

NCT03401294

Recruiting

Most patients with mCRC are treated with palliative chemotherapy and only a small number of patients with limited metastatic disease achieve long-term remission following metastasectomy. There is a growing need for more effective treatment in patients with liver-only mCRC to improve the rate of curative resection without compromising QOL.The current study is informed by our patient's needs. It aims to evaluate the rate of conversion therapy in patients with unresectable liver-only mCRC using the... Read More

Gender:

ALL

Ages:

Between 18 years and 70 years

Trial Updated:

05/07/2025

Locations: Allan Balir Cancer Center, Regina, Saskatchewan

Conditions: Metastatic Colorectal Cancer

Learn More ›

Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors

NCT05800964

Recruiting

The primary objective of this study is to: * Evaluate the safety and tolerability of AMG 305 in adult participants * Determine the optimal biologically active dose (OBD), at or below the maximum tolerated dose (MTD) with MTD 1 as the maximum tolerated starting dose and MTD 2 as the maximum tolerated target dose * Determine the recommended phase 2 dose (RP2D)

Gender:

ALL

Ages:

Between 18 years and 100 years

Trial Updated:

05/07/2025

Locations: City of Hope National Medical Center, Duarte, California +25 locations

City of Hope National Medical Center, Duarte, California

Hackensack University Medical Center, Hackensack, New Jersey

New York University Cancer Institute, New York, New York

Thomas Jefferson University, Philadelphia, Pennsylvania

Sarah Cannon Research Institute, Nashville, Tennessee

Next Oncology, San Antonio, Texas

Chris OBrien Lifehouse, Camperdown, New South Wales

Peter MacCallum Cancer Centre, Melbourne, Victoria

Princess Margaret Cancer Centre, Toronto, Ontario

Institut Universitaire du Cancer Toulouse Oncopole, Toulouse cedex 9, Not set

Gustave Roussy, Villejuif, Not set

Universitaetsklinikum Dresden, Dresden, Not set

Universitaetsklinikum Essen, Essen, Not set

Universitaetsklinikum Wuerzburg, Wuerzburg, Not set

National Cancer Center Hospital East, Kashiwa-shi, Chiba

Seoul National University Hospital, Seoul, Not set

Asan Medical Center, Seoul, Not set

Hospital Universitari Vall d Hebron, Barcelona, Cataluña

Hospital Clinic i Provincial de Barcelona, Barcelona, Cataluña

Hospital Universitario 12 de Octubre, Madrid, Not set

Hospital Universitario Madrid Sanchinarro, Madrid, Not set

Beatson West of Scotland Cancer Centre, Glasgow, Not set

Sarah Cannon Research Institute UK, London, Not set

Christie Hospital, Manchester, Not set

Freeman Hospital, Newcastle, Not set

Royal Marsden Hospital, Sutton, Not set

Conditions: Advanced Solid Tumors

Learn More ›

A Natural History Study in Participants With Congenital Myasthenic Syndromes (CMS) Due to Mutations in DOK7, MUSK, AGRN, or LRP4

NCT06078553

Recruiting

Participants will attend up to 4 study visits to collect clinical assessments. The assessments will evaluate participants' symptoms and quality of life to understand disease activity in patients with CMS due to mutations in DOK7, MUSK, AGRN, or LRP4.

Gender:

ALL

Ages:

2 years and above

Trial Updated:

05/07/2025

Locations: UC Davis Health - UC Davis Health Midtown Ambulatory Care Center, Sacramento, California +9 locations

Conditions: Congenital Myasthenic Syndrome

Learn More ›